Our Company
is committed to promoting health across communities
What does Nordic Pharma do?
Nordic Pharma sells uniquely positioned generics that bring value to customers and patients.
We spend every minute of every day figuring out how to bring historically complex prescription medications to market. Our products are generics of value to the market, not high-volume, mass-produced products.
Our Executive Team
We believe that we can deliver a better quality of life and health to the people in our communities, our families and the world.
Phil Gioia
Phil Gioia
President
Phil Gioia is President of Nordic Pharma, Inc. He is a highly experienced, passionate commercial leader with over 30 years of generic and branded pharmaceutical experience. He worked previously as Senior VP of Sales and Marketing for Generics with Barr Pharmaceuticals and was part of the team that built the Women’s Health proprietary business unit until its acquisition by Teva. Phil then led the NA Pharmaceutical Business followed by Global Head of Diversified Products and Business Development at Bausch & Lomb until its acquisition by Valeant.
Phil has extensive knowledge and demonstrated successes of business licensing, acquisitions, integrations and exits. He is also the co-founder of Vinci Pharmaceuticals, Inc., a specialty ophthalmic pharmaceutical company and a board advisor to several ophthalmology companies. Phil holds a BS degree from Montclair State University (Marketing) and an MBA from Sacred Heart University.
-
Marina Volin, Esq.VP, General Counsel & Corporate Secretary
-
Thomas SammlerVP, Commercial Operation
-
Nancy FulginitiVP, Quality
Marina Volin, Esq.
Marina Volin, Esq.
VP, General Counsel & Corporate Secretary
Marina joined Nordic Pharma in May 2020 as Vice President, General Counsel & Corporate Secretary. She oversees all legal matters for the company including contractual agreements, corporate governance, intellectual property, compliance matters and due diligence for business development opportunities.
With more than 20 years of experience representing pharmaceutical companies, Marina came to Nordic Pharma from Kintai Therapeutics of Cambridge, MA where she served as Vice President, Head of Legal and Intellectual Property. Prior to that, she served as Intellectual Property and Corporate Attorney for Windtree Therapeutics, Inc. (formerly Discovery Labs) of Warrington, PA. Marina began her legal career with the law firm Caesar Rivise, PC of Philadelphia, PA. Prior to studying law, Marina served as Scientific Assistant at the Fox Chase Cancer Center, Philadelphia, PA.
Marina earned her Juris Doctorate degree from the Temple University School of Law in Philadelphia and Master of Science and Bachelor of Science degrees in Chemical Engineering from the Gubkin Russian University of Oil and Gas in Moscow. She is a member of the New Jersey and Pennsylvania Bar Associations.
Thomas Sammler
Thomas Sammler
VP, Commercial Operation
As Vice President, Commercial Operation, Tom is responsible for the strategy and tactical execution of the Nordic Pharma Generic product portfolio as well as providing operational leadership and guidance to the Supply Chain team. He leads the identification and pursuit of profitable sales growth at the national, regional, and local levels, across Retail, Specialty, and Institutional Pharmacy. He carries out growth initiatives, such as business development activities, ensuring strong, sustained P&L performance for the company.
Before joining Nordic Pharma in September 2015, Tom was Director, Sales Operations for Impax Laboratories. In that position, he managed sales operations during the company’s integration with the Tower Holding companies. Previously, Tom held various marketing and financial positions at CorePharma, Sandoz, Endo Pharmaceuticals, and DuPont/DuPont Merck. He has experience driving revenues for both generic and branded pharmaceutical products and leading a diverse range of commercial operations, from sales teams and product marketing to supply chain logistics and strategic planning.
Tom graduated with a B.S. in Accounting from Widener University and earned his MBA in Pharmaceutical Marketing from Saint Joseph’s University.
Nancy Fulginiti
Nancy Fulginiti
VP, Quality
Nancy joined Nordic Pharma in August 2022 as Vice President, Quality. She oversees quality assurance and regulatory compliance. She has more than 25 years of experience with quality in the pharmaceutical industry. Nancy came to Nordic Pharma from CRISPR Therapeutics where she served as Vice President, Quality. Prior to that, she served as Audit Head for Novartis and Executive Director Quality for Sandoz.
Nancy holds a B.S. in Medical Technology from Thomas Jefferson University and an M.S. in Clinical Chemistry from West Chester University.
Our History
We may be new to the market, but we share the technology, maturity and capability of a nearly 70 year-old healthcare group.
1935
Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.
1950
The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.
1954
The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.
1960
Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.
2015
Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.
2015
Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..
2016
Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.
2016
Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.
2017
Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.
2017
Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.
2018
Amring enters the Medical Device with the launch of Biolon® OVD.
2018
Amring launches Arsenic Trioxide Injection – the first product from its development portfolio.
2018
Amring closes on a product acquisition deal that adds at least 3 new products to its portfolio.
2019
Amring Launches Succinylcholine Chloride Injection, a generic of Quelicin®.
2019
Amring Launches Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories.
2020
Amring acquires the global rights to LYSTEDA® (tranexamic acid).
2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program.
2021
Amring launches Isoproterenol Hydrochloride Injection, USP, a generic version of Isuprel®.
2022
Amring launches Lamotrigine Orally Disintegrating Tablets (ODT), USP, a generic of Lamictal®
2022
Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%.
2023
Nordic Pharma Group B.V. through its subsidiary Amring Pharmaceuticals Inc., completes acquisition of Visant Medical.
2024
Amring Pharmaceuticals Inc. announces name change to Nordic Pharma, Inc. under new Nordic Group, B.V. ownership.
1935
Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.
1954
The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.
1960
Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.
2015
Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..
2016
Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.
2017
Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.
2018
Amring launches Arsenic Trioxide Injection – the first product from its development portfolio.
2019
Amring Launches Succinylcholine Chloride Injection, a generic of Quelicin®.
2020
Amring acquires the global rights to LYSTEDA® (tranexamic acid).
2021
Amring launches Isoproterenol Hydrochloride Injection, USP, a generic version of Isuprel®.
2022
Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%.
2024
Amring Pharmaceuticals Inc. announces name change to Nordic Pharma, Inc. under new Nordic Group, B.V. ownership.
1950
The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.
2015
Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.
2016
Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.
2017
Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.
2018
Amring enters the Medical Device with the launch of Biolon® OVD.
2018
Amring closes on a product acquisition deal that adds at least 3 new products to its portfolio.
2019
Amring Launches Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories.
2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program.
2022
Amring launches Lamotrigine Orally Disintegrating Tablets (ODT), USP, a generic of Lamictal®
2023
Nordic Pharma Group B.V. through its subsidiary Amring Pharmaceuticals Inc., completes acquisition of Visant Medical.
Nordic Pharma, Inc. is a proud member of the global pharmaceutical community.
Our strong global network of drug technology and manufacturing gives us the quality and regulatory capability to meet the demands of various niche markets.
